Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC) von Tijeras-Raballand, A, Le Bitoux, M.A, Maillard, A, Albuquerque, M, Colnot, N, Barral, M, Dohan, A, Bonnin, P, Pocard, M, Benhadji, K, Paradis, V, Raymond, E, Harari, A, Faivre, S, De Gramont, A

Volltext

407 - Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC) von Tijeras-Raballand, A., Le Bitoux, M.A., Maillard, A., Albuquerque, M., Colnot, N., Barral, M., Dohan, A., Bonnin, P., Pocard, M., Benhadji, K., Paradis, V., Raymond, E., Harari, A., Faivre, S., De Gramont, A.

Volltext

P-200LIGHT DOSE PLAYS A CRITICAL ROLE FOR THE DISTRIBUTION OF CHEMOTHERAPY AND TUMOUR RESPONSE IN MESOTHELIOMA XENOGRAFTS PRE-TREATED BY PHOTODYNAMIC THERAPY von Wang, Xingyu, Perentes, J.Y., Wang, Y., Le Bitoux, M.A., Wagnieres, G., Vandenbergh, H., Gonzalez, M., Ris, H.B., Krueger, T.

Volltext